Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 February 2021, 07:00 HKT/SGT

Source: Maculus Therapeutix
Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform

SANTA CLARA, CA & DUBAI, Feb 19, 2021 - (ACN Newswire) - Maculus Therapeutix, a preclinical-stage biopharmaceutical company that has developed a SINGLE injection platform to treat wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and advisor for upcoming fundraising activities. Maculus plans to raise $3 million at an $8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies.

Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, called MacuBloc. Capable of delivering any FDA approved drug for wet AMD / DME to the site of the disease, with unique suitability for targeted and extended delivery of drugs to the back of the human eyes, MacuBloc offers significant benefits to Wet AMD patients such as a single intravitreal injection that lasts a year rather than the current monthly injections, and a potential reduction in inflammation, infection, doctor visits and total cost of care.

Syed H Askari, PhD, Founder, Chief Executive Officer and CTO of Maculus Therapeutix, said, "We are very excited to welcome Privity as we develop this unique product, which can bring such transformative treatment to those suffering from wet AMD and DME. Current standards of care bring numerous challenges: pain, inflammation, infection, loss of vision. Our product is designed to solve each of these challenges while significantly reducing the total cost of care.

"More importantly, our product makes it possible to replace the multiple injections required today with ONE injection for any FDA approved drug, a leap ahead of the current standards of care, and an approach which could change the lives of 200 million patients worldwide suffering from these debilitating eye diseases."

Sleem Hasan, Privity Founder and CEO, said, "Privity was founded to identify entrepreneurs with unique ideas and compelling value propositions, and Maculus fell straight into this sweet spot, speaking straight at me as I had experienced diabetic retinopathy personally, and with family members. Syed is a serial entrepreneur, while his doctoral work in Chemistry in India, the UK and Canada, and professional career in the US speak for themselves. Above all, his work with Polymers may well change the game in drug delivery."

About Maculus Therapeutix, Inc.
The Maculus team has been together in Silicon Valley for 15 years, building Medicus Biosciences, Inc, a polymer-based medical device company with current operations in San Diego, CA, while developing a platform technology for drug delivery platform for various diseases. Maculus targets the AMD and DME segments, a $15 billion market (55 million patients) growing at nearly 10% per year. For more information, visit

About Privity FZ LLE
Privity FZ LLE was founded in Dubai in 2004, an independent venture-focused advisory firm that seeks entrepreneurs with unique ideas and helps them to develop and grow. Privity is agnostic to geography and industry vertical; It focuses on the quality of the entrepreneur and the compelling value proposition of the idea. Privity draws upon its unique 4i methodology - ideas, intelligence, innovation, invention - to deliver insightful advisory and consulting services. For more information, please visit

Contact information:
Syed H Askari, CEO
Maculus Therapeutix, Inc
[email protected]

Sleem Hasan, CEO
Privity FZ LLE
[email protected]

Topic: Executive appointment
Sectors: Chemicals, BioTech, Healthcare & Pharm, MedTech
From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
UREEQA Welcomes Dean Drever, a Sculptor Who Has Produced Multi-Million Dollar Works of Art  
Mar 6, 2021 23:00 HKT/SGT
Tianyun International: Rainbow Lead Ventures Limited Becomes a New Strategic Shareholder of the Group  
Mar 6, 2021 14:10 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease  
Mar 5, 2021 16:51 HKT/SGT
Mar 5, 2021 12:53 HKT/SGT
Moonstake Partners with P2P Escrow Service Escaroo  
Mar 5, 2021 12:30 HKT/SGT
MHI Group Presents "Best Innovation 2020" Awards for Activities that Contribute to Reducing Environmental Loads  
Mar 5, 2021 08:30 HKT/SGT
CoinSmart Closes CAD$4.5 Million Seed Funding; Plans to Expand into Europe   
Mar 5, 2021 08:17 HKT/SGT
China Gas Enters into Strategic Cooperation Framework Agreement with Sinopec  
Mar 4, 2021 21:22 HKT/SGT
Acquiring Xiaoer Qingre Zhike granule, Tianda Pharmaceuticals continues to broaden its product mix and perfect its Chinese medicine whole industry chain layout  
Mar 4, 2021 19:43 HKT/SGT
Billboard Hot 100 #1 Hit of the Year Band Member Partners with UREEQA  
Mar 4, 2021 18:50 HKT/SGT
More Press release >>
More >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: